Cargando…

The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China

OBJECTIVES: Potential drug–drug interactions (DDIs) are a significant therapeutic threat among human immunodeficiency virus (HIV)-positive individuals on antiretroviral (ARV) medications. DDIs involving ARV drugs in mainland China are unknown and insufficiently described. Herein, we investigated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Huan, Gao, Liying, Gong, Xiaowen, Zaongo, Silvere D., Zhang, Tong, Wu, Hao, Ma, Ping, Huang, Xiaojie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266979/
https://www.ncbi.nlm.nih.gov/pubmed/32536872
http://dx.doi.org/10.3389/fphar.2020.00800
_version_ 1783541408074825728
author Xia, Huan
Gao, Liying
Gong, Xiaowen
Zaongo, Silvere D.
Zhang, Tong
Wu, Hao
Ma, Ping
Huang, Xiaojie
author_facet Xia, Huan
Gao, Liying
Gong, Xiaowen
Zaongo, Silvere D.
Zhang, Tong
Wu, Hao
Ma, Ping
Huang, Xiaojie
author_sort Xia, Huan
collection PubMed
description OBJECTIVES: Potential drug–drug interactions (DDIs) are a significant therapeutic threat among human immunodeficiency virus (HIV)-positive individuals on antiretroviral (ARV) medications. DDIs involving ARV drugs in mainland China are unknown and insufficiently described. Herein, we investigated the prevalence and frequencies of potential ARV DDIs in Chinese people living with HIV (PLWH), then we assessed the risk factors associated with potential DDIs. METHODS: This study was conducted with HIV-positive adults undergoing ARV medications from multiple centers across China. The latest prescription of each participant was evaluated for potential DDIs using the Liverpool HIV drug interaction database. Multivariable logistic regressions were used to evaluate the factors associated with DDIs. RESULTS: Among 600 PLWH recruited, at least one non-HIV co-medication was observed in 511 (85.2%) individuals. A total of 2566 DDIs were identified, of which 11 (0.43%) and 311 (12.89%) were of contraindicated (red-flags) and dosage/timing adjustment required (orange-flags), respectively. Multivariate regression analysis revealed a higher risk of clinically significant DDIs (red- and orange-flagged comedication) associated with: the use of boosted protease inhibitors (p < 0.0001), boosted integrase strand transfer inhibitors (p < 0.0001), and non-nucleoside reverse transcriptase inhibitors-based ARV regimen (p < 0.0001); or the use of antiinfectives for systemic use (p < 0.0001), cardiovascular system drugs (p < 0.0001), nervous system drugs (p < 0.0001), fungal infection (p = 0.0071), and Herpes simplex virus infection (p = 0.0231). CONCLUSIONS: Potential DDIs and inappropriate medications constitute a burden for people living with HIV in China. The knowledge of DDIs patterns and the scan for DDIs is crucial. Indeed, they can help to prevent drug-related adverse outcomes in such immunodeficient population.
format Online
Article
Text
id pubmed-7266979
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72669792020-06-12 The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China Xia, Huan Gao, Liying Gong, Xiaowen Zaongo, Silvere D. Zhang, Tong Wu, Hao Ma, Ping Huang, Xiaojie Front Pharmacol Pharmacology OBJECTIVES: Potential drug–drug interactions (DDIs) are a significant therapeutic threat among human immunodeficiency virus (HIV)-positive individuals on antiretroviral (ARV) medications. DDIs involving ARV drugs in mainland China are unknown and insufficiently described. Herein, we investigated the prevalence and frequencies of potential ARV DDIs in Chinese people living with HIV (PLWH), then we assessed the risk factors associated with potential DDIs. METHODS: This study was conducted with HIV-positive adults undergoing ARV medications from multiple centers across China. The latest prescription of each participant was evaluated for potential DDIs using the Liverpool HIV drug interaction database. Multivariable logistic regressions were used to evaluate the factors associated with DDIs. RESULTS: Among 600 PLWH recruited, at least one non-HIV co-medication was observed in 511 (85.2%) individuals. A total of 2566 DDIs were identified, of which 11 (0.43%) and 311 (12.89%) were of contraindicated (red-flags) and dosage/timing adjustment required (orange-flags), respectively. Multivariate regression analysis revealed a higher risk of clinically significant DDIs (red- and orange-flagged comedication) associated with: the use of boosted protease inhibitors (p < 0.0001), boosted integrase strand transfer inhibitors (p < 0.0001), and non-nucleoside reverse transcriptase inhibitors-based ARV regimen (p < 0.0001); or the use of antiinfectives for systemic use (p < 0.0001), cardiovascular system drugs (p < 0.0001), nervous system drugs (p < 0.0001), fungal infection (p = 0.0071), and Herpes simplex virus infection (p = 0.0231). CONCLUSIONS: Potential DDIs and inappropriate medications constitute a burden for people living with HIV in China. The knowledge of DDIs patterns and the scan for DDIs is crucial. Indeed, they can help to prevent drug-related adverse outcomes in such immunodeficient population. Frontiers Media S.A. 2020-05-27 /pmc/articles/PMC7266979/ /pubmed/32536872 http://dx.doi.org/10.3389/fphar.2020.00800 Text en Copyright © 2020 Xia, Gao, Gong, Zaongo, Zhang, Wu, Ma and Huang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xia, Huan
Gao, Liying
Gong, Xiaowen
Zaongo, Silvere D.
Zhang, Tong
Wu, Hao
Ma, Ping
Huang, Xiaojie
The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title_full The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title_fullStr The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title_full_unstemmed The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title_short The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
title_sort challenge of potential drug–drug interactions among people living with hiv on antiretroviral therapy: a cross-sectional study in selected provinces in china
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266979/
https://www.ncbi.nlm.nih.gov/pubmed/32536872
http://dx.doi.org/10.3389/fphar.2020.00800
work_keys_str_mv AT xiahuan thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT gaoliying thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT gongxiaowen thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT zaongosilvered thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT zhangtong thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT wuhao thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT maping thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT huangxiaojie thechallengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT xiahuan challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT gaoliying challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT gongxiaowen challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT zaongosilvered challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT zhangtong challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT wuhao challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT maping challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina
AT huangxiaojie challengeofpotentialdrugdruginteractionsamongpeoplelivingwithhivonantiretroviraltherapyacrosssectionalstudyinselectedprovincesinchina